Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theranica Ltd
Medicare beneficiaries suffering from migraines will soon have access to an innovate drug-free treatment at the touch of their smartphones.
The US Centers for Medicare & Medicaid Services (CMS) has announced the July schedule for its virtual Healthcare Common Procedure Coding System (HCPCS) public meetings.
The FDA granted a de novo clearance to Theranica’s Nerivio Migra smartphone-controlled remote electrical neuromodulation device for acute treatment of migraine headaches.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week's approvals include a PMA for Qiagen's therascreen PIK3CA RGQ real-time qualitative PCR assay kit as a companion diagnostic to Novartis' Piqray (alpelisib) and a de novo for Theranica's Nerivio Migra smartphone-controlled wearable device to treat migraines.
- Digital Health
- Rehabilitation Equipment and Devices
- Other Names / Subsidiaries
- Siano Mobile Silicon
- Theranica Bio-Electronics Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.